CRL Chart

1 Month

	Date	Diff
	2025-04-21	-3.19 %
Charles River Laboratories (CRL) stock declined by 3.19% following the announcement of a reduction in a significant institutional investor's holdings, alongside analysts lowering their price targets for the stock, which raised concerns among investors about its future performance.
	2025-04-17	+1.73 %
Charles River Laboratories (CRL) stock rose by 1.73% due to being highlighted as one of the biotech stocks to watch, indicating positive market sentiment and interest in innovative healthcare solutions offered by biotech firms.
	2025-04-15	-0.64 %
Charles River Laboratories (CRL) stock dropped 0.64% as several institutional investors, including Russell Investments Group Ltd., reduced their stakes, which may have contributed to the downward pressure on the stock price amid mixed analyst ratings and a slight decline in revenue compared to the previous year. Charles River Laboratories (CRL) stock declined by 0.64% after Zacks Research lowered its Q2 2026 earnings per share estimates from $2.67 to $2.46, which likely prompted negative investor sentiment. Charles River Laboratories (CRL) stock fell by 0.64% to $99.56 amid volatility in the biotech sector, likely due to the inherent risks and uncertainties associated with clinical trials and regulatory processes that characterize the industry.
	2025-04-14	+6.87 %
Charles River Laboratories (CRL) stock rose 6.87% following a surge in interest towards weight loss drugs and the company's strategic positioning within a booming market, highlighted by innovations and competitive pressure from emerging players like Kailera Therapeutics.
	2025-04-11	-0.2 %
Charles River Laboratories (CRL) stock fell by 0.2% in a tumultuous market characterized by widespread declines due to heightened economic and geopolitical uncertainties following President Trump's severe tariff announcements and concerns over a potential recession. The stock went down primarily because it was among the worst performers on the S&P 500 during this volatile period, with a significant overall downturn in the market affecting the pharmaceutical sector where CRL operates.
	2025-04-10	-28.13 %
Charles River Laboratories (CRL) stock plummeted by 28.13% following a downgrade in Q1 2025 earnings estimates by Zacks Research, which lowered its forecast from $2.08 to $2.07 per share, alongside several analysts adjusting their target prices downward. Charles River Laboratories (CRL) stock experienced a significant decline of 28.13% due to a combination of institutional investors reducing their stakes and lowered price targets from several research analysts, despite the company reporting better-than-expected quarterly earnings.
	2025-04-04	-2.89 %
Charles River Laboratories (CRL) stock fell by 2.89% primarily due to investor concerns regarding its comparative performance against other medical companies like Takeda Pharmaceutical and Xenetic Biosciences, though specific reasons for the decline were not detailed in the article. Charles River Laboratories (CRL) stock declined by 2.89% following JPMorgan Chase & Co.'s disclosure of a 4.3% decrease in its stake in the company, along with recent downgrades and target price reductions by several analysts.
	2025-04-02	+2.25 %
Charles River Laboratories' stock (CRL) rose by 2.25% following a series of institutional investors adjusting their positions, alongside a positive quarterly earnings report that exceeded analysts' expectations, highlighting the company's ongoing financial stability and growth potential.
	2025-03-28	-1.59 %
Charles River Laboratories (CRL) stock decreased by 1.59% primarily due to adjustments made by institutional investors, including a notable reduction by Commonwealth Equity Services LLC, and revisions of target prices by several brokerage firms which reflected a more cautious outlook on the company's performance.
	2025-03-24	-0.18 %
Charles River Laboratories International (CRL) stock declined by 0.18% after being downgraded from a buy to a neutral rating by Goldman Sachs, reducing its price target from $190 to $170, which reflects a broader trend of analysts adjusting their ratings and price targets for the company.
	2025-03-20	-4.91 %
Charles River Laboratories (CRL) stock fell by 4.91% due to uncertainties in the oncology small molecule drugs market, despite the overall expected growth of the sector and strategic investments by leading pharmaceutical companies.
	2025-03-18	+1.1 %
Charles River Laboratories (CRL) stock rose 1.1% due to positive investor sentiment following a strong quarterly earnings report that exceeded analyst expectations, despite Zacks Research revising its earnings per share estimates downward for Q1 2025.
	2025-03-17	+2.32 %
Charles River Laboratories' stock (CRL) rose by 2.32% possibly due to increased institutional investment, with Zurcher Kantonalbank growing its stake by 12.9% and other hedge funds making significant increases in their holdings during the fourth quarter.
	2025-03-14	+2.46 %
Charles River Laboratories (CRL) stock rose 2.46% due to increased institutional investment interest, as several hedge funds significantly raised their stakes in the company during the recent quarters, indicating growing confidence in its performance.
	2025-03-13	-2.15 %
Charles River Laboratories (CRL) stock declined by 2.15% following a series of analysts downgrading their target prices and rating outlooks, indicating concerns about future performance despite a recent quarterly earnings beat.
	2025-03-11	-4.85 %
Charles River Laboratories (CRL) shares fell by 4.85% due to a combination of reduced target prices from analysts and ongoing concerns about its revenue decline, despite reporting better-than-expected earnings.
	2025-03-10	-0.45 %
Charles River Laboratories (CRL) stock fell by 0.45% due to institutional selling pressures, with notable insider sales and various brokerage firms lowering their price targets, affecting investor sentiment.
	2025-03-07	+3.93 %
Charles River Laboratories (CRL) stock increased by 3.93% due to significant institutional investor interest, with several hedge funds acquiring new positions or substantially increasing their stakes in the company. Charles River Laboratories International, Inc. (CRL) stock rose by 3.93% following a positive quarterly earnings report that exceeded analysts’ expectations, despite receiving an overall "Hold" recommendation from brokerages.
	2025-03-06	+1.03 %
Charles River Laboratories (CRL) stock rose by 1.03% after Citigroup upgraded its rating from "sell" to "neutral" and increased its price target from $155 to $175, indicating a positive outlook and potential upside for investors.
	2025-03-05	+1.97 %
Charles River Laboratories (CRL) stock rose by 1.97% following an upgrade from a "sell" to a "neutral" rating by Redburn Atlantic, along with a target price increase, suggesting potential for further upside.
	2025-02-25	-2 %
Charles River Laboratories (CRL) stock fell by 2.0% due to the downgrade of Q1 2025 earnings estimates by William Blair, which lowered its EPS forecast from $2.41 to $2.06, leading to a negative market reaction and several other analysts adjusting their price targets and ratings on the stock. Charles River Laboratories (CRL) stock fell 2.0% following a series of target price downgrades by multiple analysts and overall market volatility, despite recent insider purchases that initially boosted the stock price.
	2025-02-21	+0.47 %
Charles River Laboratories International, Inc. (CRL) stock rose 0.47% after announcing better-than-expected quarterly earnings of $2.66 per share, surpassing analyst estimates and driving investor confidence. The stock went up due to the company's strong earnings performance that exceeded analysts' expectations, along with positive revenue results despite a slight decline year-over-year.
	2025-02-19	+6.87 %
Charles River Laboratories (CRL) stock rose by 6.87% as institutional investors, including the New York State Teachers Retirement System and Creative Planning, adjusted their holdings, indicating increased investor interest and market activity despite some recent price target reductions from analysts. Charles River Laboratories (CRL) stock rose by 6.87% due to a combination of institutional investment activity and analysts’ price target adjustments that reflect a potentially positive outlook for the company's performance.
	2025-02-18	+1.58 %
Charles River Laboratories (CRL) stock rose by 1.58% due to significant modifications in institutional investors' holdings, including a large increase from Wellington Management Group and others, which reflects growing confidence in the company's prospects amidst varying analyst ratings and target price adjustments. Charles River Laboratories (CRL) stock rose by 1.58% due to increased institutional investment, including a 12.6% position increase by V Square Quantitative Management LLC, indicating growing confidence in the company despite mixed ratings from analysts.
	2025-02-14	-0.77 %
Charles River Laboratories (CRL) stock closed down by 0.77% largely due to a series of downgrades from multiple investment analysts, which has negatively affected investor confidence and expectations regarding the company's future performance. Charles River Laboratories (CRL) stock recently decreased by 0.77%, primarily due to multiple analysts downgrading their ratings and target prices for the stock.
	2025-02-11	-3.12 %
Charles River Laboratories (CRL) stock fell by 3.12% as several research firms issued downward revisions on its price targets and ratings, leading to diminished investor confidence ahead of its upcoming earnings announcement.
	2025-02-10	-2.38 %
Charles River Laboratories (CRL) stock fell by 2.38% following a reduction in stake by abrdn plc, which cut its holdings by 5.5%, alongside mixed analysts' ratings and target price adjustments, contributing to investor uncertainty.
	2025-02-07	-1.49 %
Charles River Laboratories International, Inc. (CRL) stock dropped by 1.49% amid cautious recommendations from analysts, with most rating it as a "reduce" and several lowering their price targets following a quarterly revenue decline despite beating earnings expectations. The decline in CRL's stock price can be attributed to analysts issuing negative ratings and downward price target adjustments, reflecting concerns over its revenue performance compared to the previous year.
	2025-02-05	+1.69 %
Charles River Laboratories (CRL) experienced a 1.69% increase in stock price, despite a downgrade in its price target from JPMorgan to $175, due to positive quarterly earnings that exceeded analysts’ expectations and a potential upside reflected in various price targets. The stock likely went up because it reported better-than-expected earnings per share and revenue, which can boost investor confidence even amidst mixed analyst ratings. Charles River Laboratories (CRL) stock rose 1.69% likely due to increased stake purchases by institutional investors, such as Tokio Marine Asset Management Co., and strong earnings performance that exceeded analyst expectations, despite recent mixed ratings from analysts.
	2025-02-04	+0.93 %
Charles River Laboratories (CRL) stock rose by 0.93% amid concerns about potential tariffs on trade with Canada and Mexico, which impacted many companies in the S&P 500, but its strong performance can be attributed to its lesser exposure to these markets compared to others.
	2025-02-03	-1.91 %
Charles River Laboratories (CRL) stock declined by 1.91% due to an increase in short interest and several downgrades from analysts, indicating a loss of confidence in the stock's performance.
	2025-01-30	+2.43 %
Charles River Laboratories (CRL) stock increased by 2.43% due to significant interest from institutional investors, with various firms boosting their stakes, indicating strong confidence in the company's potential following its recent earnings report that exceeded expectations despite a slight revenue decline.
	2025-01-27	+0.53 %
Charles River Laboratories (CRL) stock increased by 0.53% likely due to significant investment activity from hedge funds, with some firms dramatically boosting their positions in the company, which reflects growing confidence among institutional investors.
	2025-01-24	-1.13 %
Charles River Laboratories (CRL) stock dropped by 1.13% following a downgrade by William Blair from "outperform" to "market perform," amid a broader trend of negative analyst ratings and reduced target prices for the stock.
	2025-01-21	+3.86 %
Charles River Laboratories (CRL) stock increased by 3.86% amid mixed analyst ratings, with attempts to lower FY2025 earnings estimates being outpaced by positive sentiment following a recent quarterly earnings report that beat expectations. The stock's rise can be attributed to a combination of strong quarterly performance and market reactions despite reduced earnings projections from some analysts.
	2025-01-17	-1.39 %
Charles River Laboratories (CRL) stock fell by 1.39% due to analysts issuing mixed ratings, with some downgrading the stock and reducing price targets, which suggests uncertainty about the company's future performance despite its recent earnings beat. Charles River Laboratories (CRL) stock fell by 1.39% last night, driven by a combination of lowered analyst ratings, including a downgrade to "sell" by Citigroup and a general consensus rating of "hold" among analysts.
	2025-01-13	+2.16 %
Shares of Charles River Laboratories (CRL) rose by 2.16% following positive quarterly earnings, where the company exceeded analysts' EPS expectations and reported higher-than-expected revenue, despite a slight decrease in year-over-year revenue.
	2025-01-08	-0.97 %
Charles River Laboratories (CRL) stock declined by 0.97% due to broader market factors impacting investor sentiment.
	2025-01-07	+0.12 %
Charles River Laboratories (CRL) stock rose by 0.12% due to significant acquisitions by large investors, including Everence Capital Management, which acquired a new stake, and positive earnings results that beat expectations, despite some mixed analyst ratings on the stock.
	2024-12-27	-0.26 %
Charles River Laboratories (CRL) stock fell by 0.26% following a downgrade in their Q1 2025 earnings per share estimates from Zacks Research, which lowered its forecast from $2.42 to $2.35, contributing to a negative sentiment among investors.
	2024-12-19	-0.55 %
Charles River Laboratories (CRL) stock experienced a 0.55% decline likely influenced by various factors, including a mixed outlook from analysts, with some reducing their price targets, as well as recent insider selling that raised concerns among investors. Charles River Laboratories (CRL) stock fell 0.55% after being assigned a consensus "Reduce" rating by analysts, with several brokerages lowering their price targets, indicating a general lack of confidence in the stock's near-term performance.
	2024-12-10	-2.33 %
Charles River Laboratories International, Inc. (CRL) experienced a 2.33% decline in stock value likely due to significant selling by institutional investors, including a 70.7% reduction in holdings by Fmr LLC and downgrades from several analysts affecting investor sentiment.
	2024-12-09	+5.18 %
Charles River Laboratories (CRL) stock rose by 5.18% following increased investment from institutional investors, such as Janus Henderson Group PLC, which raised its holdings in the company by 7.6% during the third quarter, indicating growing confidence in the company's performance and potential for future growth.
	2024-12-06	+0.14 %
Charles River Laboratories (CRL) stock rose by 0.14% following a series of institutional investors boosting their holdings, including Glenmede Trust Co. NA increasing its position by 9.5%, indicating positive investor sentiment toward the company's financial performance and future prospects.
	2024-12-05	-3.92 %
Charles River Laboratories (CRL) stock declined by 3.92% following a series of downgrades from analysts, a significant insider stock sale, and a year-over-year revenue decrease despite beating EPS estimates in their recent earnings report.
	2024-12-02	+1.1 %
Charles River Laboratories (CRL) stock rose 1.1%, likely due to positive investor sentiment following its recent better-than-expected earnings report and ongoing institutional investment activities, including a $1 billion stock buyback program indicating management's confidence in the company's valuation. Charles River Laboratories (CRL) stock rose by 1.1% amid revisions in earnings estimates by Zacks Research, indicating investors may have responded positively to the company's prior earnings beat and overall market sentiment despite some downward adjustments in future earnings expectations.
	2024-11-29	-0.27 %
Charles River Laboratories (CRL) stock fell by 0.27% due to a consensus rating of "Reduce" from analysts, with several downgrades and reduced price targets reflecting concerns about its recent quarterly earnings performance and overall market sentiment.
	2024-11-26	-1.76 %
Charles River Laboratories (CRL) stock fell by 1.76%, likely due to broader market uncertainties influenced by political and economic factors, including anticipated regulation changes and general investor sentiment.
	2024-11-25	+2.82 %
Charles River Laboratories (CRL) stock increased by 2.82% due to strong earnings results that exceeded analyst expectations, a significant ongoing share repurchase program indicating management's belief in the stock's undervaluation, and favorable institutional investment activity.
	2024-11-20	+0.97 %
Charles River Laboratories (CRL) stock increased by 0.97% due to strong quarterly earnings that exceeded analysts' expectations and the announcement of a share buyback program, suggesting confidence in the stock's undervaluation. Charles River Laboratories (CRL) stock rose by 0.97% following an 8.6% increase in holdings by CIBC Asset Management and other institutional investors, indicating increased confidence in the company despite mixed analyst ratings and a recently initiated share repurchase program suggesting management believes the stock is undervalued. Charles River Laboratories (CRL) stock rose 0.97% as institutional investors continued to modify their positions, reflecting confidence in the company's growth potential despite mixed analyst ratings and recent earnings results.
	2024-11-19	-0.75 %
Charles River Laboratories (CRL) stock decreased by 0.75% following a series of insider sales and mixed analyst ratings, indicating potential concerns about the company's future performance amidst a decline in quarterly earnings year-over-year.
	2024-11-04	+0.84 %
Charles River Laboratories (CRL) stock is up 0.84% primarily due to strong earnings performance exceeding consensus estimates and the announcement of a substantial $1 billion share buyback program, indicating the company's confidence in its own valuation. Charles River Laboratories (CRL) stock increased by 0.84% likely due to recent positive developments such as a robust quarterly earnings report that surpassed earnings estimates, a substantial share buyback program indicating management’s belief in the company’s undervalued stock, and ongoing interest from institutional investors. Charles River Laboratories (CRL) stock increased by 0.84% amid a mixed analyst outlook, with a consensus "Reduce" recommendation and a significant stock repurchase program indicating management's belief that shares are undervalued, alongside strong quarterly earnings surpassing expectations.

1
500 / page